Monopar Therapeutics MNPR Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Monopar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Monopar Therapeutics’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monopar Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monopar Therapeutics's operating cash flow?
- Monopar Therapeutics (MNPR) reported operating cash flow of -$3.47M in Q1 2026.
- How has Monopar Therapeutics's operating cash flow changed year-over-year?
- Monopar Therapeutics's operating cash flow increased by 38.7% year-over-year, from -$5.66M to -$3.47M.
- What is the long-term trend for Monopar Therapeutics's operating cash flow?
- Over 4 years (2021 to 2025), Monopar Therapeutics's operating cash flow has grown at a 13.6% compound annual growth rate (CAGR), from -$7.32M to -$12.2M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.